<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03068897</url>
  </required_header>
  <id_info>
    <org_study_id>2017-7566</org_study_id>
    <nct_id>NCT03068897</nct_id>
  </id_info>
  <brief_title>Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain</brief_title>
  <official_title>Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized study, based in emergency departments, in which the investigators&#xD;
      determine the utility of adding various skeletal muscle relaxants to standard therapy, which&#xD;
      consists of ibuprofen and an educational session. Patients will be enrolled at the time of an&#xD;
      emergency visit and followed for three months to determine outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 3, 2017</start_date>
  <completion_date type="Actual">October 11, 2018</completion_date>
  <primary_completion_date type="Actual">July 11, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Medications provided to patients are encapsulated. Medications vials are labelled with investigational stickers.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Functional Impairment as Measured by the Roland Morris Disability Questionnaire (RMDQ)</measure>
    <time_frame>Baseline and 7 days</time_frame>
    <description>The Roland Morris Disability Questionnaire (RMDQ) is a 24 item instrument that evaluates the impact of low back pain on one's daily life. It is most sensitive for patients with mild to moderate disability due to acute, sub-acute or chronic low back pain. Each question can be answered as either a &quot;yes&quot; or &quot;no&quot;. The score ranges from 0 to 24 where a higher score reflects greater impairment and, therefore, worsening in the quality of life. The change in RMDQ is obtained by subtracting the RMDQ score at one week after discharge from the baseline score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience Change in Low Back Pain</measure>
    <time_frame>Baseline and 7 days</time_frame>
    <description>Change is assessed by verbal numerical scale of which 0 represents no pain and 10 represents the worst pain imaginable between the baseline ED visit and the one week follow-up (baseline - 1 week ). The baseline questions will refer to the time period immediately prior to ED presentation (Before you came to the ER today, were you able to…..)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Need for Medication for Low Back Pain</measure>
    <time_frame>7 days</time_frame>
    <description>Patients will be asked what medications they have used for low back pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Disability</measure>
    <time_frame>7 days</time_frame>
    <description>Disability will be assessed with the Roland-Morris Disability Questionnaire (RMDQ) where patients are asked to tick a box if they agree with 24 statements regarding their ability to perform certain activities (dressing, housework, walking). If the don't agree with the statement (able to perform those activities) they need to leave the tick-box blank or unchecked. Every agreement (tick) counts as a point and an absolute value is formed (min: 0, max: 24). The higher the value the higher the disability level.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Metaxalone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen 600mg mg + metaxalone 400-800mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tizanidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen 600mg mg + tizanidine 2-4mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baclofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen 600mg mg + baclofen 10-20 mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ibuprofen 600mg mg + placebo, 1 or 2 capsules, every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metaxalone</intervention_name>
    <description>Metaxalone 400-800mg</description>
    <arm_group_label>Metaxalone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tizanidine</intervention_name>
    <description>Tizanidine 2-4mg</description>
    <arm_group_label>Tizanidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen</intervention_name>
    <description>Baclofen 10-20mg</description>
    <arm_group_label>Baclofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen 600 mg</intervention_name>
    <description>Ibuprofen</description>
    <arm_group_label>Baclofen</arm_group_label>
    <arm_group_label>Metaxalone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Tizanidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Educational intervention</intervention_name>
    <description>Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
    <arm_group_label>Baclofen</arm_group_label>
    <arm_group_label>Metaxalone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Tizanidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Present to ED primary for management of LBP, defined as pain originating between the&#xD;
             lower border of the scapulae and the upper gluteal folds. Flank pain, that is pain&#xD;
             originating from tissues lateral to the paraspinal muscles, will not be included.&#xD;
&#xD;
          -  Musculoskeletal etiology of low back. Patients with non-musculoskeletal etiologies&#xD;
             such as urinary tract infection, ovarian cysts, or influenza like illness will be&#xD;
             excluded. The primary clinical diagnosis, at the conclusion of the ED visit, must be a&#xD;
             diagnosis consistent with non-traumatic, non-radicular, musculoskeletal LBP.&#xD;
&#xD;
          -  Patient is to be discharged home. Patients admitted to the hospital are more likely to&#xD;
             be treated with parenteral medication and therefore are not appropriate for this&#xD;
             study.&#xD;
&#xD;
          -  Age 18-64 Enrollment will be limited to adults younger than 65 years because of the&#xD;
             increased risk of adverse medication effects in the elderly.&#xD;
&#xD;
          -  Non-radicular pain. Patients will be excluded if the pain radiates below the gluteal&#xD;
             folds in a radicular pattern.&#xD;
&#xD;
          -  Pain duration &lt;2 weeks (336 hours). Patients with more than two weeks of pain are at&#xD;
             increased risk of poor pain and functional outcomes.(9)&#xD;
&#xD;
          -  Prior to the acute attack of LBP, back pain cannot occur more frequently than once per&#xD;
             month. Patients with more frequent back pain are at increased risk of poor pain and&#xD;
             functional outcomes.(9)&#xD;
&#xD;
          -  Non-traumatic LBP: no substantial and direct trauma to the back within the previous&#xD;
             month&#xD;
&#xD;
          -  Functionally impairing back pain: A baseline score of &gt; 5 on the Roland-Morris&#xD;
             Disability Questionnaire&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not available for follow-up&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Chronic pain syndrome defined as use of any analgesic medication on a daily or&#xD;
             near-daily basis&#xD;
&#xD;
          -  Allergic to or intolerant of investigational medications&#xD;
&#xD;
          -  Contra-indications to non-steroidal anti-inflammatory drugs: 1) history of&#xD;
             hypersensitivity to NSAIDs or aspirin 2) active or history of peptic ulcer disease,&#xD;
             chronic dyspepsia, or active or history of gastrointestinal bleed 3) Severe heart&#xD;
             failure (NYHA 2 or worse) 4) hypertension (JNC7 stage 2 or worse) 5) Chronic kidney&#xD;
             disease 3 or worse 6) Current use of anti-coagulants 7) Hepatitis 8) Alcoholism&#xD;
&#xD;
          -  Contra-indications to muscle relaxants: 1) Concurrent use of centrally acting opioids;&#xD;
             2) Renal impairment; 3) Liver abnormality including cirrhosis or elevated enzymes 4)&#xD;
             Use of any of the following medications: fluvoxamine, fluoroquinolones, amiodarone,&#xD;
             mexiletine, propafenone, verapamil, cimetidine, famotidine, acyclovir, ticlopidine,&#xD;
             oral contraceptive pills&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>per patient</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 16, 2017</study_first_submitted>
  <study_first_submitted_qc>March 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <results_first_submitted>November 7, 2019</results_first_submitted>
  <results_first_submitted_qc>August 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2020</results_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Tizanidine</mesh_term>
    <mesh_term>Baclofen</mesh_term>
    <mesh_term>Metaxalone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be available</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT03068897/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metaxalone</title>
          <description>Ibuprofen 600mg mg + metaxalone 400-800mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Metaxalone: Metaxalone 400-800mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
        </group>
        <group group_id="P2">
          <title>Tizanidine</title>
          <description>Ibuprofen 600mg mg + tizanidine 2-4mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Tizanidine: Tizanidine 2-4mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
        </group>
        <group group_id="P3">
          <title>Baclofen</title>
          <description>Ibuprofen 600mg mg + baclofen 10-20 mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Baclofen: Baclofen 10-20mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Ibuprofen 600mg mg + placebo, 1 or 2 capsules, every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="80"/>
                <participants group_id="P4" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="79"/>
                <participants group_id="P4" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metaxalone</title>
          <description>Ibuprofen 600mg mg + metaxalone 400-800mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Metaxalone: Metaxalone 400-800mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
        </group>
        <group group_id="B2">
          <title>Tizanidine</title>
          <description>Ibuprofen 600mg mg + tizanidine 2-4mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Tizanidine: Tizanidine 2-4mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
        </group>
        <group group_id="B3">
          <title>Baclofen</title>
          <description>Ibuprofen 600mg mg + baclofen 10-20 mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Baclofen: Baclofen 10-20mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Ibuprofen 600mg mg + placebo, 1 or 2 capsules, every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="80"/>
            <count group_id="B5" value="320"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" spread="10"/>
                    <measurement group_id="B2" value="40" spread="11"/>
                    <measurement group_id="B3" value="39" spread="12"/>
                    <measurement group_id="B4" value="39" spread="11"/>
                    <measurement group_id="B5" value="39" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="80"/>
                    <measurement group_id="B5" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of low back pain in hours</title>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="80"/>
                    <count group_id="B4" value="80"/>
                    <count group_id="B5" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="24" upper_limit="83"/>
                    <measurement group_id="B2" value="48" lower_limit="24" upper_limit="72"/>
                    <measurement group_id="B3" value="72" lower_limit="24" upper_limit="114"/>
                    <measurement group_id="B4" value="72" lower_limit="24" upper_limit="96"/>
                    <measurement group_id="B5" value="60" lower_limit="24" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Functional Impairment as Measured by the Roland Morris Disability Questionnaire (RMDQ)</title>
        <description>The Roland Morris Disability Questionnaire (RMDQ) is a 24 item instrument that evaluates the impact of low back pain on one's daily life. It is most sensitive for patients with mild to moderate disability due to acute, sub-acute or chronic low back pain. Each question can be answered as either a &quot;yes&quot; or &quot;no&quot;. The score ranges from 0 to 24 where a higher score reflects greater impairment and, therefore, worsening in the quality of life. The change in RMDQ is obtained by subtracting the RMDQ score at one week after discharge from the baseline score.</description>
        <time_frame>Baseline and 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metaxalone</title>
            <description>Ibuprofen 600mg mg + metaxalone 400-800mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Metaxalone: Metaxalone 400-800mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
          </group>
          <group group_id="O2">
            <title>Tizanidine</title>
            <description>Ibuprofen 600mg mg + tizanidine 2-4mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Tizanidine: Tizanidine 2-4mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
          </group>
          <group group_id="O3">
            <title>Baclofen</title>
            <description>Ibuprofen 600mg mg + baclofen 10-20 mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Baclofen: Baclofen 10-20mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Ibuprofen 600mg mg + placebo, 1 or 2 capsules, every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Impairment as Measured by the Roland Morris Disability Questionnaire (RMDQ)</title>
          <description>The Roland Morris Disability Questionnaire (RMDQ) is a 24 item instrument that evaluates the impact of low back pain on one's daily life. It is most sensitive for patients with mild to moderate disability due to acute, sub-acute or chronic low back pain. Each question can be answered as either a &quot;yes&quot; or &quot;no&quot;. The score ranges from 0 to 24 where a higher score reflects greater impairment and, therefore, worsening in the quality of life. The change in RMDQ is obtained by subtracting the RMDQ score at one week after discharge from the baseline score.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="8.0" upper_limit="12.3"/>
                    <measurement group_id="O2" value="11.2" lower_limit="9.2" upper_limit="13.2"/>
                    <measurement group_id="O3" value="10.6" lower_limit="8.6" upper_limit="12.7"/>
                    <measurement group_id="O4" value="11.1" lower_limit="9.0" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experience Change in Low Back Pain</title>
        <description>Change is assessed by verbal numerical scale of which 0 represents no pain and 10 represents the worst pain imaginable between the baseline ED visit and the one week follow-up (baseline - 1 week ). The baseline questions will refer to the time period immediately prior to ED presentation (Before you came to the ER today, were you able to…..)</description>
        <time_frame>Baseline and 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metaxalone</title>
            <description>Ibuprofen 600mg mg + metaxalone 400-800mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Metaxalone: Metaxalone 400-800mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
          </group>
          <group group_id="O2">
            <title>Tizanidine</title>
            <description>Ibuprofen 600mg mg + tizanidine 2-4mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Tizanidine: Tizanidine 2-4mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
          </group>
          <group group_id="O3">
            <title>Baclofen</title>
            <description>Ibuprofen 600mg mg + baclofen 10-20 mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Baclofen: Baclofen 10-20mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Ibuprofen 600mg mg + placebo, 1 or 2 capsules, every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experience Change in Low Back Pain</title>
          <description>Change is assessed by verbal numerical scale of which 0 represents no pain and 10 represents the worst pain imaginable between the baseline ED visit and the one week follow-up (baseline - 1 week ). The baseline questions will refer to the time period immediately prior to ED presentation (Before you came to the ER today, were you able to…..)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Need for Medication for Low Back Pain</title>
        <description>Patients will be asked what medications they have used for low back pain</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metaxalone</title>
            <description>Ibuprofen 600mg mg + metaxalone 400-800mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Metaxalone: Metaxalone 400-800mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
          </group>
          <group group_id="O2">
            <title>Tizanidine</title>
            <description>Ibuprofen 600mg mg + tizanidine 2-4mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Tizanidine: Tizanidine 2-4mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
          </group>
          <group group_id="O3">
            <title>Baclofen</title>
            <description>Ibuprofen 600mg mg + baclofen 10-20 mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Baclofen: Baclofen 10-20mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Ibuprofen 600mg mg + placebo, 1 or 2 capsules, every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Need for Medication for Low Back Pain</title>
          <description>Patients will be asked what medications they have used for low back pain</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levels of Disability</title>
        <description>Disability will be assessed with the Roland-Morris Disability Questionnaire (RMDQ) where patients are asked to tick a box if they agree with 24 statements regarding their ability to perform certain activities (dressing, housework, walking). If the don't agree with the statement (able to perform those activities) they need to leave the tick-box blank or unchecked. Every agreement (tick) counts as a point and an absolute value is formed (min: 0, max: 24). The higher the value the higher the disability level.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metaxalone</title>
            <description>Ibuprofen 600mg mg + metaxalone 400-800mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Metaxalone: Metaxalone 400-800mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
          </group>
          <group group_id="O2">
            <title>Tizanidine</title>
            <description>Ibuprofen 600mg mg + tizanidine 2-4mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Tizanidine: Tizanidine 2-4mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
          </group>
          <group group_id="O3">
            <title>Baclofen</title>
            <description>Ibuprofen 600mg mg + baclofen 10-20 mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Baclofen: Baclofen 10-20mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Ibuprofen 600mg mg + placebo, 1 or 2 capsules, every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Disability</title>
          <description>Disability will be assessed with the Roland-Morris Disability Questionnaire (RMDQ) where patients are asked to tick a box if they agree with 24 statements regarding their ability to perform certain activities (dressing, housework, walking). If the don't agree with the statement (able to perform those activities) they need to leave the tick-box blank or unchecked. Every agreement (tick) counts as a point and an absolute value is formed (min: 0, max: 24). The higher the value the higher the disability level.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="16"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="15"/>
                    <measurement group_id="O3" value="6" lower_limit="0" upper_limit="16"/>
                    <measurement group_id="O4" value="3" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Metaxalone</title>
          <description>Ibuprofen 600mg mg + metaxalone 400-800mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Metaxalone: Metaxalone 400-800mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
        </group>
        <group group_id="E2">
          <title>Tizanidine</title>
          <description>Ibuprofen 600mg mg + tizanidine 2-4mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Tizanidine: Tizanidine 2-4mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
        </group>
        <group group_id="E3">
          <title>Baclofen</title>
          <description>Ibuprofen 600mg mg + baclofen 10-20 mg every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Baclofen: Baclofen 10-20mg&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Ibuprofen 600mg mg + placebo, 1 or 2 capsules, every 8 hours, as needed for low back pain, x 7 days.&#xD;
All participants receive a brief educational intervention.&#xD;
Ibuprofen 600 mg: Ibuprofen&#xD;
Educational intervention: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal complaint</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>urinary complaint</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Benjamin W. Friedman</name_or_title>
      <organization>Montefiore</organization>
      <phone>718-920-6626</phone>
      <email>befriedm@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

